A Phase I/II Trial of Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed or Refractory Multiple Myeloma: Hoosier Cancer Research Network MM08-141

Trial Profile

A Phase I/II Trial of Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed or Refractory Multiple Myeloma: Hoosier Cancer Research Network MM08-141

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 20 Jul 2018

At a glance

  • Drugs Bendamustine (Primary) ; Bortezomib; Doxorubicin liposomal; Filgrastim
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Jul 2018 Status changed from active, no longer recruiting to discontinued.
    • 20 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
    • 20 Dec 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top